TG Therapeutics公司宣布,其针对初治复发型多发性硬化症(RMS)患者开展的ULTIMATE I和II期3期试验的事后分析数据,已在《免疫学前沿》期刊上发表。该数据的发布为评估相关疗法在特定患者群体中的表现提供了进一步的深入见解。
TG Therapeutics公司宣布,其针对初治复发型多发性硬化症(RMS)患者开展的ULTIMATE I和II期3期试验的事后分析数据,已在《免疫学前沿》期刊上发表。该数据的发布为评估相关疗法在特定患者群体中的表现提供了进一步的深入见解。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.